1. Academic Validation
  2. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice

Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice

  • Int Immunopharmacol. 2013 Jun;16(2):139-47. doi: 10.1016/j.intimp.2013.04.014.
Na Chen 1 Qianchao Wu Gefu Chi Lanan Wassy Soromou Jinli Hou Yanhong Deng Haihua Feng
Affiliations

Affiliation

  • 1 College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130062, PR China.
Abstract

Prime-O-glucosylcimifugin is an active chromone isolated from Saposhnikovia root which has been reported to have various activities, such as anti-convulsant, Anticancer, anti-inflammatory properties. The purpose of this study was to evaluate the effect of prime-O-glucosylcimifugin on acute lung injury (ALI) induced by lipopolysaccharide in mice. BALB/c mice received intraperitoneal injection of Prime-O-glucosylcimifugin 1h before intranasal instillation (i.n.) of lipopolysaccharide (LPS). Concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and interleukin (IL)-6 in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary histological changes were evaluated by hematoxylin-eosin, myeloperoxidase (MPO) activity in the lung tissue and lung wet/dry weight ratios were observed. Furthermore, the mitogen-activated protein kinases (MAPK) signaling pathway activation and the phosphorylation of IκBα protein were determined by Western blot analysis. Prime-O-glucosylcimifugin showed promising anti-inflammatory effect by inhibiting the activation of MAPK and NF-κB signaling pathway.

Figures
Products